Abstract:Background and aim: Acute-on-chronic liver failure (ACLF) has a high mortality rate. The role of granulocyte colony-stimulating factor (G-CSF) in ACLF remains controversial. Monocytes/macrophages are core immune cells, which are involved in the initiation and progression of liver failure; however, the effect of G-CSF on monocytes/macrophages is unclear. The study aimed to verify the clinical efficacy of G-CSF and explore the effect of it on monocytes in hepatitis B virus (HBV)-related ACLF (HBV-ACLF) paitents. Methods: We performed a large randomized controlled clinical trial for the treatment of HBV-ACLF using G-CSF. A total of 111 patients with HBV-ACLF were prospectively randomized into the G-CSF group (5 μg/kg G-CSF every day for 6 days, then every other day until day 18) or the control group (standard therapy). All participants were followed up for at least 180 days. The relationship between monocyte count and mortality risk was analyzed. The effect of G-CSF on the phenotype and function of monocytes from patients with HBV-ACLF was evaluated using flow cytometry in vivo and in vitro experiments. Results: The survival probability of the G-CSF group at 180 days was higher than that of the control group (72.2% vs. 53.8%, P = 0.0142). In the G-CSF-treated group, the monocyte counts on days 0 and 7 were independently associated with an evaluated mortality risk in the fully adjusted model (Model 3) [at day 0: hazard ratio (HR) 95% confidence interval (CI): 15.48 (3.60, 66.66), P = 0.0002; at day 7: HR (95% CI): 1.10 (0.50, 2.43), P=0.8080]. Further analysis showed that after treatment with G-CSF in HBV-ACLF patients, the expression of M1-like markers (HLA-DR and CD86) in monocytes decreased (HLA-DR: P = 0.0148; CD86: P = 0.0764). The expression of MerTK (M2-like marker) increased (P = 0.0002). The secretion of TNF-α, IL-6, and IL-10 from monocytes decreased without lipopolysaccharide (LPS) stimulation (TNF-α: P < 0.0001; IL-6: P= 0.0025; IL-10: P = 0.0004) or with LPS stimulation (TNF-α: P = 0.0439; P = 0.0611; IL-10: P = 0.0099). Similar effects were observed in vitro experiments. Conclusion: G-CSF therapy confers a survival benefit to patients with HBV-ACLF. G-CSF can promote the anti-inflammatory/pro-restorative phenotype (M2-like) transition of monocytes, which may contribute to the recovery of ACLF.Clinical Trial Registration Number: ClinicalTrials.gov, identifier (NCT02331745).

The efficacy and safety of granulocyte colony-stimulating factor in the treatment of acute-on-chronic liver failure: A systematic review and meta-analysis

Therapeutic Effect and Safety of Granulocyte Colony-Stimulating Factor Therapy for Acute-On-Chronic Liver Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Effectiveness of Granulocyte Colony-Stimulating Factor for Patients with Acute-on-chronic Liver Failure: a Meta-Analysis

Effects of Granulocyte Colony-Stimulating Factor on Patients with Liver Failure: a Meta-Analysis.

Prediction Value of Model for End-Stage Liver Disease Scoring System on Prognosis in the Acute on Chronic Liver Failure Patients with Plasma Exchange Treatment.

S1924 Impact of Granulocyte Colony Stimulating Factor on the Survival of Patients With Decompensated Cirrhosis and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-analysis

Granulocyte colony-stimulating factor treatment ameliorates liver injury and improves survival in rats with D-galactosamine-induced acute liver failure.

Granulocyte Colony-Stimulating Factor Accelerates the Recovery of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure by Promoting M2-Like Transition of Monocytes

Granulocyte-monocyte Colony-Stimulating Factor for the Treatment of Sepsis: a Meta Analysis

[Effects of Granulocyte Colony-Stimulating Factor on Hepatocyte Apoptosis in Acute Liver Failure: Experiment with Rats].

GCSF Deficiency Attenuates Nonalcoholic Fatty Liver Disease Through Regulating GCSFR-SOCS3-JAK-STAT3 Pathway and Immune Cells Infiltration.

Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Rats with Acute Liver Failure

Granulocyte Colony-Stimulating Factor Plus Pentoxifylline Increases Short-Term Survival in Patients with Severe Alcoholic Hepatitis: a Network Meta-Analysis.

Granulocyte Colony-Stimulating Factor in Severe Alcoholic Hepatitis: A Randomized Pilot Study

Protective Effects of Granulocyte Colony-Stimulating Factor on Acute Hepatic Failure Induced by D-galactosamine/lipopolysaccharide in Mice

Associations of Granulocyte Colony-Stimulating Factor with Toxicities and Efficacy of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory Multiple Myeloma

Comparing the efficacy and safety of long and short acting drugs targeting Granulocyte Colony-stimulating Factor in cancer patients after chemotherapy: A systematic review and meta-analysis of randomized controlled trials

Preliminary Investigation of Effect of Granulocyte Colony Stimulating Factor on Amyotrophic Lateral Sclerosis

Granulocyte Transfusion Combined with Granulocyte Colony Stimulating Factor in Severe Infection Patients with Severe Aplastic Anemia: A Single Center Experience from China

Granulocyte colony-stimulating factor effects on neurological and motor function in animals with spinal cord injury: a systematic review and meta-analysis

Clinical performance of stem cell therapy in patients with acute-on-chronic liver failure: a systematic review and meta-analysis